

DOCKET NO.: ISIC0001-103 (ISIS-4945)

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Ching-Lcou Teng et al.

Confirmation No.: 6046

Serial No.: 10/029,598

Group Art Unit: 1635

File Date: December 21, 2001

Examiner: Epps, Janet L.

For: COMPOSITIONS AND METHODS FOR A NON-PARENTERAL DELIVERY OF OLIGONUCLEOTIDES

Express Mail Number: EV147 608 834US
Deposited: August 28, 2003

**TERMINAL DISCLAIMER TO OBVIATE A DOUBLE
PATENTING REJECTION OVER A PRIOR PATENT**

The owner, Isis Pharmaceuticals, Inc., of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. **6,096,722**. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all

claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

(Check either box 1 or 2 below, if appropriate)

1. ☐ For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.
- ☐ The required statement under 37 CFR 3.73(b) is attached.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. ☒ The undersigned is an attorney of record.

FEE STATUS

- ☐ 3. Applicant(s) has previously claimed small entity status under 37 CFR §1.27.
- ☒ 4. Applicant(s) by its/their undersigned attorney, claims small entity status under 37 CFR §1.27 as:
- ☐ an Independent Inventor
 - ☐ a Small Business Concern
 - ☐ a Nonprofit Organization
 - ☐ Small Entity - \$55.00


DOCKET NO.: ISIC0001-103
(ISIS-4945)

-3-

PATENT

☒ 5. Other than a Small Entity - \$110.00

Date: August 28, 2003



Michael P. Straher
Registration No. 38,325

COZEN O'CONNOR, P.C.
1900 Market Street
Philadelphia, PA 19103
Telephone: (215) 665-5548
Facsimile: (215) 665-2013

PHILATEL904045